- Global stocks diverge on renewed US inflation fears
- France coach Deschamps to step down after 2026 World Cup
- French magazine run by autistic journalists hits newsstands
- US, Canadian and Australian travellers now face UK entry fee
- France urges European Commission to be firm against Musk interference
- Wildfire sparks panicked evacuations in Los Angeles suburbs
- Nobel winner Ressa tells AFP 'dangerous times' ahead after Meta ends US fact-checking
- Indonesia upholds iPhone 16 sales ban after Apple offers $1 bn investment
- Dutch great Kluivert named Indonesia coach in hunt for World Cup spot
- UK's Catherine turns 43 hoping for better year
- France coach Deschamps says will leave after 2026 World Cup
- South Syria fighters reluctant to give up weapons: spokesman
- Dutch great Kluivert named coach of Indonesia
- New Zealand crush Sri Lanka by 113 runs in 2nd ODI to win series
- West Ham cancel Lopetegui press conference as sacking rumours swirl
- Questions remain over South African involvement in Champions Cup
- OpenAI chief Sam Altman denies sister's sexual abuse accusations
- Hundreds rally for South Korea's Yoon as new arrest bid beckons
- Bangladesh orders banks to assist UK minister graft probe
- Germans turn to balcony solar panels to save money
- Theekshana hat-trick restricts NZ to 255-9 in 2nd Sri Lanka ODI
- Young's buzzer-beater lifts Hawks, Celtics down Nuggets
- Grief and nostalgia in India's 'Jimmy Carter village'
- Venezuela's 'colectivos' ready to pounce as opposition plans protest
- Thai police hunt suspect over Cambodian politician shooting
- Venezuela on tenterhooks ahead of rival protests, Maduro swearing-in
- Devajit Saikia: lawyer, modest player and next India cricket chief
- S. Korea's impeached President Yoon holds out in capital 'fortress'
- Samsung warns fourth-quarter profit to miss forecasts
- China's viral wild boar hunters attract fame and concern
- Forgotten but not gone: Covid keeps killing, five years on
- Is the world ready for the next pandemic?
- Trump's provocative, often confusing, US foreign policy is back
- Rescuers search for survivors after quake in China's Tibet kills at least 126
- Brazil gears up for first climate conference in Amazon
- In Brazil, an Amazon reforestation project seeks to redeem carbon markets
- Djokovic with point to prove against younger rivals at Australian Open
- Asian markets mixed after Wall St hit by US inflation fears
- Mexicans offered $1,300 to hand in a machine gun
- Venezuela arrests two Americans, five other 'mercenaries'
- Iraqi archaeologists piece together ancient treasures ravaged by IS
- Big Tech rolls out the red carpet for Trump
- Kyrgios suffers new injury setback days before Australian Open
- Former US president Carter lies in state after somber Washington procession
- US company Firefly Aerospace to launch for Moon next week
- Don't eat your Christmas tree, warns Belgium food agency
- No proof fentanyl produced in Mexico, president says
- Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
- Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Hemogenyx Pharmaceuticals PLC Announces Placing to raise £340,000
BCC | -1.69% | 118.22 | $ | |
CMSD | -1.15% | 23.46 | $ | |
JRI | -1.88% | 12.22 | $ | |
CMSC | -1.12% | 23.23 | $ | |
SCS | -2.14% | 11.2 | $ | |
GSK | 0.38% | 34.09 | $ | |
NGG | -0.46% | 58.6 | $ | |
RIO | -0.33% | 58.19 | $ | |
BTI | -0.52% | 36.78 | $ | |
AZN | -0.3% | 66.64 | $ | |
RYCEF | -0.42% | 7.17 | $ | |
RBGPF | 100% | 59.31 | $ | |
BCE | -0.34% | 23.86 | $ | |
RELX | 0.72% | 45.98 | $ | |
BP | 2.54% | 31.83 | $ | |
VOD | -0.71% | 8.41 | $ |
US panel recommends nonprescription use of contraception pill
A US panel of health experts voted Wednesday in favor of making birth control pills available without a prescription, a move backed by reproductive rights advocates especially in the wake of a Supreme Court ruling overturning the national right to abortion.
The independent panel voted unanimously that the benefits of allowing the medicine, Opill, to be sold over the counter, outweighed the risks and would reduce hurdles associated with visiting a doctor that impact lower income groups disproportionately.
"I believe that the efficacy and safety of this birth control form was established over half a century ago," said panelist Jolie Haun of the James A. Haley Veterans' Hospital.
"We now have been presented with ample data demonstrating the effective safe use and benefits for people who want to have access to reproductive autonomy."
The committee's votes are usually accepted by the Food and Drug Administration, which means the pill, which is made by HRA Pharma, might be available without prescription in the coming weeks.
While likely, approval is not assured. FDA scientists highlighted safety concerns, such as the potential impact on people with a history or current diagnosis of breast cancer, or whether they would understand the pill needs to be taken the same time every day to prevent pregnancy.
"There is also concern that some consumers may not consistently use the product correctly on a chronic basis and be at risk for pregnancy, but not recognize that they are pregnant because of the irregular bleeding that would be ascribed to the known side effect," the FDA wrote in a document.
The push for a non-prescription pill has taken on new urgency in light of a Supreme Court decision overturning the constitutional right to abortion, leading to numerous bans and severe restrictions in conservative states.
It has received support from health groups such as the American Medical Association and American College of Obstetricians and Gynecologists.
If the pill is approved, the US would join more than 100 other countries where the pill is available without a prescription, including the UK which requires a consultation with a pharmacist.
Opill is known as a "mini pill" because it contains progestin only.
Another company, Cadence, is in talks with the FDA about making its combination pill, which contains both estrogen and progestin, available over the counter.
P.Martin--AMWN